Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Cash (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Change in Cash for 3 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 107.62% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.3 million, a 0.47% change, with the full-year FY2025 number at -$13.3 million, changed 0.47% from a year prior.
  • Change in Cash was $1.2 million for Q4 2025 at Artiva Biotherapeutics, up from -$3.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $21.6 million in Q3 2024 to a low of -$15.6 million in Q4 2024.
  • A 3-year average of -$2.7 million and a median of -$4.1 million in 2024 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 107.62% in 2025; the steepest drop was 113.68% in 2025.
  • Artiva Biotherapeutics' Change in Cash stood at -$12.4 million in 2023, then decreased by 26.37% to -$15.6 million in 2024, then surged by 107.62% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Change in Cash are $1.2 million (Q4 2025), -$3.0 million (Q3 2025), and -$1.9 million (Q2 2025).